Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 81Colorectal Neoplasms 39Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Liver Neoplasms 14Neoplasms 11Melanoma 11Carcinoma, Renal Cell 11Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Transitional Cell 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Head and Neck Neoplasms 7Cholangiocarcinoma 7Rectal Neoplasms 6Neoplasm Metastasis 6Colonic Neoplasms 6Urinary Bladder Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Merkel Cell 5Biliary Tract Neoplasms 5Prostatic Neoplasms 4Sarcoma 3Lung Neoplasms 3Gallbladder Neoplasms 3

Interventions

trifluridine tipiracil drug combination 1romidepsin 1futibatinib 1cabozantinib 1atezolizumab 1Trabectedin 1TAS-116 1Ramucirumab 1Imatinib Mesylate 1HhAntag691 1Gemcitabine 1Fluorouracil 1Dasatinib 1Cisplatin 1Carboplatin 1Bevacizumab 14-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × atezolizumab × Gastrointestinal × Clear all
NCT06066138 2026-06-04

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
30 enrolled
DermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡